Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangyiqing is a Traditional Chinese Medicine (TCM) granule formulation developed by the First Affiliated Hospital of Henan University of Traditional Chinese Medicine. It is specifically indicated for the treatment of immune thrombocytopenia (ITP) in pediatric patients, particularly those presenting with the 'Yin deficiency and blood heat' syndrome according to TCM diagnostic criteria. The formulation is designed to regulate the immune system, stabilize platelet levels, and reduce bleeding symptoms by addressing underlying systemic imbalances. It is currently being evaluated in clinical trials to establish its safety and therapeutic efficacy in children with ITP.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangyiqing.